High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 5, 2011, Pages

  Moura, Margarida M ^a,b   Cavaco, Branca M ^a,b   Pinto, António E ^a   Leite, Valeriano ^a,b  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAF GENE; CARCINOGENESIS; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; H RAS GENE; HUMAN; HUMAN TISSUE; K RAS GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; N RAS GENE; ONCOGENE; ONCOGENE RAS; PREVALENCE; PRIORITY JOURNAL; RET GENE; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA;

CALCITONIN; CARCINOMA, MEDULLARY; CODON; DNA; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FLOW CYTOMETRY; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 79955669404     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1921     Document Type: Article

References (36)

1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BA 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460 (Pubitemid 23179393)
2. Eng C 1999 RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380-393 (Pubitemid 29022417)
3. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JW, van Amstel HK, Romeo G, Lips CJ, Buys CH 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376
4. Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C 1994 Somatic andMEN2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 3:1259-1262 (Pubitemid 24255456)
5. Jhiang SM, Fithian L, Weghorst CM, Clark OH, Falko JM, O'Dorisio TM, Mazzaferri EL 1996 RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 6:115-121 (Pubitemid 26153009)
6. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG 1996 Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44:249-257 (Pubitemid 26063401)
7. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F 1996 Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619-1622 (Pubitemid 26118602)
8. Wohllk N, Cote GJ, BugalhoMM,Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF 1996 Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745 (Pubitemid 26339948)
9. Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L 1997 Molecular analysis of theRETproto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Eur J Endocrinol 136:423-426 (Pubitemid 27207150)
10. Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G, Cascone E, Marzano L, Paracchi S, Busnardo B, Girelli ME, Bellastella A, Colantuoni V 1998 Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 137:51-57
11. Shan L, Nakamura M, Nakamura Y, Utsunomiya H, Shou N, Jiang X, Jing X, Yokoi T, Kakudo K 1998 Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas. Jpn J Cancer Res 89:883-886 (Pubitemid 28486812)
12. Uchino S, Noguchi S, Adachi M, Sato M, Yamashita H, Watanabe S, Murakami T, Toda M, Murakami N, Yamashita H 1998 Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas. Jpn J Cancer Res 89:411-418 (Pubitemid 28226922)
13. Bockhorn M, Frilling A, Kalinin V, Schröder S, Broelsch CE 1999 No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. Langenbecks Arch Surg 384:60-64 (Pubitemid 29225320)
14. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T, Takahashi M 1999 Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn J Cancer Res 90:1231-1237
15. Marsh DJ, Theodosopoulos G, Martin-Schulte K, Richardson AL, Philips J, Röher HD, Delbridge L, Robinson BG 2003 Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 88:1866-1872 (Pubitemid 36623416)
16. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D, Bendlova B 2008 Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284:21-27
17. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682-687 (Pubitemid 351398539)
18. Ameur N, Lacroix L, Roucan S, Roux V, Broutin S, Talbot M, Dupuy C, Caillou B, Schlumberger M, Bidart JM 2009 Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Endocr Relat Cancer 16:1261-1272
19. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ, Leite V 2009 Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100:1777-1783
20. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, SunYN,Juan T, Stepan DE, Sherman SI 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801
21. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, HallNC,Wakely Jr PE, Vasko VV, SajiM,Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, ShahMH2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330
22. Vasko V, FerrandM,Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752 (Pubitemid 36724451)
23. Zhu Z, GandhiM,NikiforovaMN,Fischer AH, Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-77
24. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAFmutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differ- entiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404 (Pubitemid 37452745)
25. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU, Komminoth P 2004 BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 11:855-860 (Pubitemid 40065557)
26. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365-1368 (Pubitemid 38368438)
27. Fenton C, Anderson J, Lukes Y, Dinauer CA, Tuttle RM, Francis GL 1999 Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J Endocrinol Invest 22:781-789
28. Bockhorn M, Frilling A, Kalinin V, Schröder S, Broelsch CE 2000 Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 108:49-53 (Pubitemid 30160435)
29. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Brodeur GM1991 Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res 51:1596-1599
30. Okazaki M, Miya A, Tanaka N, Miki T, Yamamoto M, Motomura K, Miyauchi A, Mori T, Takai S 1989 Allele loss on chromosome 10 and point mutation of ras oncogenes are infrequent in tumors of MEN 2A. Henry Ford Hosp Med J 37:112-115 (Pubitemid 20207541)
31. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, GazouliM2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28:305-308
32. DeLellis RA, Lloyd RV, Heitz PU, Eng C 2004 World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Vol. 8. Lyon, France: IARC Press; 50
33. Sobin LH, Wittekind C 2002 TNM classification of malignant tumours (UICC). 6th ed. Hoboken, NJ: John Wiley and Sons; 52-56
34. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA 1983 Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333-1335 (Pubitemid 14226962)
35. Imyanitov EN, Grigoriev MY, Gorodinskaya VM, Kuligina ES, Pozharisski KM, Togo AV, Hanson KP 2001 Partial restoration of degraded DNA from archival paraffin-embedded tissues. Biotechniques 31:1000-1002 (Pubitemid 33063307)
36. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R 2008 Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7:1001-1006